The use of specialty drugs in the U.S. has skyrocketed in recent years driven primarily by an increase in chronic condition diagnosis and the number of new medications on the market. Krishnanjan ...
Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal) TA1118 7 January 2026 7 January 2026 ...